In the past 10 years, there has been tremendous progress made in the field of gene therapy. Effective treatments of Leber congenital amaurosis, hemophilia, and spinal muscular atrophy have been largely based on the efficiency and safety of adeno-associated vectors. Myocardial gene therapy has been tested in patients with heart failure using adeno-associated vectors with no safety concerns but lacking clinical improvements. Cardiac gene therapy is adapting to the new developments in vectors, delivery systems, targets, and clinical end points and is poised for success in the near future.

Original languageEnglish
Pages (from-to)601-613
Number of pages13
JournalCirculation Research
Issue number5
StatePublished - 2018


  • Aav
  • Clinical trial
  • Gene therapy
  • Heart failure
  • Leber congenital amaurosis
  • Myocardium


Dive into the research topics of 'Human cardiac gene therapy'. Together they form a unique fingerprint.

Cite this